TH9507

TH9507, also known as TH9507, is a synthetic 44-amino acid peptide representing a modified form of human growth hormone-releasing hormone (GHRH). Its molecular structure includes modifications intended to increase its half-life and stability in research settings compared to naturally occurring GHRH. This peptide functions by binding to and activating the growth hormone-releasing hormone receptor (GHRHR) in the anterior pituitary gland, subsequently stimulating the pulsatile release of growth hormone (GH). The research history of GHRH analogs like TH9507 stems from early investigations into the regulation of growth hormone secretion. Initial studies focused on identifying and characterizing the endogenous GHRH peptide. Subsequent research involved synthesizing modified versions to understand structural-activity relationships and to develop tools for studying GH regulation in various biological models. TH9507 specifically has been a subject of interest due to its sustained action profile, allowing for prolonged investigation into its effects on GH dynamics. Biochemically, TH9507 acts as a potent secretagogue, initiating a cascade of intracellular events upon GHRHR binding that leads to the synthesis and release of growth hormone. Its specificity for the GHRHR makes it a valuable tool for isolating and studying the GHRH-GH axis independently of other neuroendocrine pathways. Research applications include studies on pituitary function, metabolic regulation, and the role of GH in tissue development and maintenance in in vitro and in vivo laboratory models.